[99mTc]Tc-HFAPi SPECT/CT 在消化系统恶性肿瘤患者中的作用:首次临床经验
单中心前瞻性诊断效能研究纳入40例疑似或确诊消化系统肿瘤患者,行[99mTc]Tc-HFAPi SPECT/CT,并与增强CT比较。对疑似转移灶,[99mTc]Tc-HFAPi灵敏度89.66% vs 增强CT 68.97%(P=0.03),特异度97.9% vs 85.4%(P=0.03),肝转移特异度100%(24/24),导致20.0%(8/40)TNM分期和15.0%(6/40)肿瘤治疗管理改变。
要点
- [99mTc]Tc-HFAPi在肝、胰、胆囊生理性分布,肾、脾、甲状腺分布较少。
- 对非手术原发灶诊断灵敏度与增强CT相似(94.29% vs 100%,P=0.5)。
- 对疑似转移灶灵敏度、特异度均高于增强CT(P=0.03),肝转移特异度100%。
核心结论
- [99mTc]Tc-HFAPi在检测远处转移尤其是识别肝转移方面诊断效能优于增强CT。
研究设计与样本
- 单中心前瞻性诊断效能研究,纳入40例疑似或确诊消化系统肿瘤患者,2021年1月至6月行[99mTc]Tc-HFAPi SPECT/CT;4例代表性患者于注射后10、30、90、150、240分钟行全身平面显像用于动态生物分布和剂量学估算;所有患者于注射后60-90分钟进行最佳采集时间点显像,并用SUVmax和T/B比值进行定量或半定量分析。
主要发现
- 40例患者共115个病灶;非手术原发灶诊断灵敏度[99mTc]Tc-HFAPi为94.29%(33/35)vs 增强CT 100%(35/35),P=0.5;局部复发检出[99mTc]Tc-HFAPi为100%(3/3);疑似转移灶诊断灵敏度[99mTc]Tc-HFAPi 89.66%(26/29)vs 增强CT 68.97%(20/29),P=0.03,特异度[99mTc]Tc-HFAPi 97.9%(47/48)vs 增强CT 85.4%(41/48),P=0.03;肝转移诊断特异度[99mTc]Tc-HFAPi为100%(24/24);[99mTc]Tc-HFAPi导致20.0%(8/40)TNM分期改变和15.0%(6/40)肿瘤治疗管理改变。
关键数值与推荐
- [99mTc]Tc-HFAPi在肝、胰腺、胆囊可见生理性分布,在肾脏、脾脏和甲状腺分布较少;最佳采集时间为注射后60-90分钟;定量或半定量采用SUVmax和T/B比值;诊断效能与增强CT比较采用McNemar检验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, PET/CT imaging with radiolabelled FAP inhibitors (FAPIs) has been widely evaluated in diverse diseases. However, rare report has been published using SPECT/CT, a more available imaging method, with [99mTc]Tc-labelled FAPI. In this study, we evaluated the potential effect of [99mTc]Tc-HFAPi in clinical analysis for digestive system tumours. METHODS: This is a single-centre prospective diagnostic efficiency study (Ethic approved No.: XJTU1AF2021LSK-021 of the First Affiliated Hospital of Xi'an Jiaotong University and ChiCTR2100048093 of the Chinese Clinical Trial Register). Forty patients with suspected or confirmed digestive system tumours underwent [99mTc]Tc-HFAPi SPECT/CT between January and June 2021. For dynamic biodistribution and dosimetry estimation, whole-body planar scintigraphy was performed at 10, 30, 90, 150, and 240 min post-injection in four representative patients. Optimal acquisition time was considered in all the patients at 60-90 min post-injection, then quantified or semi-quantified using SUVmax and T/B ratio was done. The diagnostic performance of [99mTc]Tc-HFAPi was calculated and compared with those of contrast-enhanced CT (ceCT) using McNemar test, and the changes of tumour stage and oncologic management were recorded. RESULTS: Physiological distribution of [99mTc]Tc-HFAPi was observed in the liver, pancreas, gallbladder, and to a lesser extent in the kidneys, spleen and thyroid. Totally, 40 patients with 115 lesions were analysed. The diagnostic sensitivity of [99mTc]Tc-HFAPi for non-operative primary lesions was similar to that of ceCT (94.29% [33/35] vs 100% [35/35], respectively; P = 0.5); in local relapse detection, [99mTc]Tc-HFAPi was successfully detected in 100% (n = 3) of patients. In the diagnosis of suspected metastatic lesions, [99mTc]Tc-HFAPi exhibited higher sensitivity (89.66% [26/29] vs 68.97% [20/29], respectively, P = 0.03) and specificity (97.9% [47/48] vs 85.4% [41/48], respectively, P = 0.03) than ceCT, especially with 100% (24/24) specificity in the diagnosis of liver metastases, resulting in 20.0% (8/40) changes in TNM stage and 15.0% (6/40) changes in oncologic management. CONCLUSION: [99mTc]Tc-HFAPi demonstrates a greater diagnostic efficiency than ceCT in the detection of distant metastasis, especially in identifying liver metastases.
引用
- Jia X, Li X, Jia B, et al. The role of [99mTc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: first clinical experience. Eur J Nucl Med Mol Imaging. 2022. PMID: 36477400. doi:10.1007/s00259-022-06068-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。